ViewRay - VRAY Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRAY shares.
View VRAY analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month price objectives for ViewRay's shares. Their VRAY share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 89.2% from the stock's current price.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.

ViewRay's stock was trading at $5.51 at the beginning of 2022. Since then, VRAY shares have decreased by 32.8% and is now trading at $3.70.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VRAY earnings forecast.

ViewRay, Inc. (NASDAQ:VRAY) announced its quarterly earnings results on Tuesday, August, 2nd. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The business earned $22.15 million during the quarter, compared to analyst estimates of $19.57 million. ViewRay had a negative trailing twelve-month return on equity of 75.54% and a negative net margin of 131.20%.

ViewRay updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00 million-$104.00 million, compared to the consensus revenue estimate of $96.82 million.

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRAY stock can currently be purchased for approximately $3.70.

ViewRay (NASDAQ:VRAY) has a market capitalization of $669.74 million and generates $70.12 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 267 workers across the globe.

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.